<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id><journal-title>BMC Pulmonary Medicine</journal-title><issn pub-type="epub">1471-2466</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2466-8-12</article-id><article-id pub-id-type="pmid">18700005</article-id><article-id pub-id-type="doi">10.1186/1471-2466-8-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Schaaf</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>schaaf@uni-luebeck.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Liebau</surname><given-names>Cornelia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cornelia.liebau@gmx.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Kurowski</surname><given-names>Volkhard</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>daniel.droemann@uk-sh.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Droemann</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>volkhard.kurowski@innere2.uni-luebeck.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Dalhoff</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Dalhoff@uni-luebeck.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Medical Clinic III, University of L&#x000fc;beck, L&#x000fc;beck, Germany</aff><aff id="I2"><label>2</label>Medical Clinic II, University of L&#x000fc;beck, L&#x000fc;beck, Germany</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2008</year></pub-date><volume>8</volume><fpage>12</fpage><lpage>12</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2466/8/12"/><history><date date-type="received"><day>28</day><month>2</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Schaaf et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Schaaf et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Schaaf Bernhard schaaf@uni-luebeck.de </dc:author><dc:title> Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Pulmonary Medicine 8(1): 12-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2466(2008)8:1&#x0003c;12&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2466</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Neutrophil products like matrix metalloproteinases (MMP), involved in bacterial defence mechanisms, possibly induce lung damage and are elevated locally during hospital- acquired pneumonia (HAP). In HAP the virulence of bacterial species is known to be different. The aim of this study was to investigate the influence of high-risk bacteria like <italic>S. aureus </italic>and pseudomonas species on pulmonary MMPconcentration in human pneumonia.</p></sec><sec sec-type="methods"><title>Methods</title><p>In 37 patients with HAP and 16 controls, MMP-8, MMP-9 and tissue inhibitors of MMP (TIMP) were analysed by ELISA and MMP-9 activity using zymography in bronchoalveolar lavage (BAL).</p></sec><sec><title>Results</title><p>MMP-9 activity in mini-BAL was increased in HAP patients versus controls (149 &#x000b1; 41 vs. 34 &#x000b1; 11, p &#x0003c; 0.0001). In subgroup analysis, the highest MMP concentrations and activity were seen in patients with high-risk bacteria: patients with high-risk bacteria MMP-9 1168 &#x000b1; 266 vs. patients with low-risk bacteria 224 &#x000b1; 119 ng/ml p &#x0003c; 0.0001, MMP-9 gelatinolytic activity 325 &#x000b1; 106 vs. 67 &#x000b1; 14, p &#x0003c; 0.0002. In addition, the MMP-8 and MMP-9 concentration was associated with the state of ventilation and systemic inflammatory marker like CRP.</p></sec><sec><title>Conclusion</title><p>Pulmonary MMP concentrations and MMP activity are elevated in patients with HAP. This effect is most pronounced in patients with high-risk bacteria. Artificial ventilation may play an additional role in protease activation.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Hospital-acquired pneumonia (HAP) is associated with high mortality rates of up to 30% in intensive care unit-related pneumonia [<xref ref-type="bibr" rid="B1">1</xref>], most prominent in ventilated patients [<xref ref-type="bibr" rid="B2">2</xref>]. Innate defense mechanism activating phagocytes locally in the lung play an important role in the elimination of bacteria, but overactivation might also be harmful to the host. Clinically, infections with <italic>P. aeruginosa </italic>and <italic>S. aureus </italic>are associated with the most severe HAP[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Besides bacterial virulence factors, the induction of the innate immunity might differ between different bacterial species.</p><p>An essential component of host defence against bacterial infection are polymorphonuclear neutrophils (PMN). In response to an inflammatory stimulus, PMN migrate into the alveolar compartment as primary effector cells to kill and phagocyte microorganisms. PMN are known to contain matrix metalloproteinases (MMP) [<xref ref-type="bibr" rid="B5">5</xref>]. MMP are a family of zinc- and calcium-dependent endopeptidases with 28 members to date that are subclassified into six groups. MMP-8 (neutrophil Collagenase) and MMP-9 (Gelatinase 2) are synthesized and stored in PMN [<xref ref-type="bibr" rid="B6">6</xref>]. During infection, antigen contact induces PMN activation and MMP release [<xref ref-type="bibr" rid="B7">7</xref>]. Elevated blood and bronchoalveolar lavage (BAL) levels of different MMP have been found in community and hospital-acquired pneumonia (8;9). MMP are thought to induce bacterial clearance possibly via induction of proinflammatory cytokines, since MMP knockout mice have a higher bacterial load and higher mortality after experimental infection [<xref ref-type="bibr" rid="B10">10</xref>]. Besides antimicrobial activity, free proteolytic activity of MMP might cause local tissue damage via degradation of different components of the extracellular matrix [<xref ref-type="bibr" rid="B11">11</xref>]. The possibility of local pulmonary damage is reduced via inhibitors of MMP, most importantly tissue inhibitors of MMP (TIMP) [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Apart from bacterial infection, mechanical ventilation might induce pulmonary inflammation. It is well-known that biotrauma associated with mechanical ventilation causes PMN recruitment [<xref ref-type="bibr" rid="B13">13</xref>]. MMP release and activation induced by cytokine release (IL-6, IL-8, TNF-alpha) are thought to be involved in lung damage in this setting [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Since both the type of bacterial infection and biotrauma due to invasive ventilation might influence the pulmonary release and activation of MMP, we asked the following questions:</p><p>1. Are infections with high-risk bacteria (<italic>P. aeruginosa </italic>and <italic>S. aureus</italic>) associated with a more pronounced pulmonary MMP release and activation than low-risk bacteria?</p><p>2. Is invasive ventilation associated with pulmonary MMP release and activation?</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study group</title><p>Thirty-seven patients with hospital-acquired pneumonia (HAP) were studied. Sixteen persons who underwent elective cardiac surgery were studied during ventilation (ventilation &#x0003c; 12 hours) as controls (controls published before [<xref ref-type="bibr" rid="B8">8</xref>], HAP patients not published before). The study protocol was approved of by the local ethics committee and informed written consent was obtained from all patients or close relatives.</p></sec><sec><title>Definition of hospital-acquired pneumonia (HAP)</title><p>HAP was defined, according to ATS criteria adapted by Kollef et al. [<xref ref-type="bibr" rid="B4">4</xref>], as hospitalisation for &#x0003e; 48 hours, a new and persistent infiltrate (radiographically present for &#x0003e; 48 hours), PLUS at least two of the following criteria: [<xref ref-type="bibr" rid="B1">1</xref>] core temperature &#x0003e; 38.5 or &#x0003c; 36&#x000b0;C, [<xref ref-type="bibr" rid="B2">2</xref>] blood leukocytes &#x0003e; 10/&#x003bc;l or &#x0003c; 4/&#x003bc;l or [<xref ref-type="bibr" rid="B3">3</xref>] purulent tracheal secretions [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Only patients with a positive bacterial culture in mini-bronchoalveolar lavage [&#x02265; 10<sup>3 </sup>CFU/ml (colony forming units)] were included in the study.</p><p>Exclusion criteria were: age &#x0003c;= 18 years, blood leukocytes &#x0003c;= 1/&#x003bc;l, malignant hematologic disease, negative bacterial culture in mini-BAL.</p></sec><sec><title>Pneumonia severity</title><p>The clinical severity of HAP was classified using the modified clinical pulmonary infection score (CPIS) described by Pugin [<xref ref-type="bibr" rid="B16">16</xref>]. In addition mortality, oxygenation index (arterial pO2/inspiratory O2 fraction: PaO2/FiO2) need of artificial ventilation and inflammatory markers (CRP, white blood count, temperature) were investigated.</p></sec><sec><title>Mini-bronchoalveolar lavage</title><p>Mini-bronchoalveolar Lavage (Mini-BAL) was either performed during bronchoscopy in non-ventilated HAP-patients (n = 22) or via suction catheter in ventilated HAP-patients (n = 15) and ventilated controls (n = 16) [<xref ref-type="bibr" rid="B17">17</xref>]. The recovery was the same in both procedures.</p><sec><title>Bronchoscopy</title><p>Bronchoscopy in non-ventilated patients was carried out under local anaesthesia with 2% lidocaine &#x02013; after premedication with 2.5&#x02013;7 mg midazolam &#x02013; using a fibre-optic bronchoscope [<xref ref-type="bibr" rid="B18">18</xref>]. 5 ml 0.15 mol/l NaCl was instilled at the site of infection and immediately aspirated (recovered volume 3&#x02013;4 ml).</p></sec><sec><title>Suction catheter</title><p>In ventilated patients 5 ml 0.15 mol/l NaCl was instilled over a sterile suction catheter below the carina and immediately aspirated (recovered volume 3&#x02013;4 ml).</p><p>One ml of the recovered volume was used for bacterial culture, the other part (2&#x02013;3 ml) was diluted with 20 ml of phosphate buffered saline (PBS), then homogenized and centrifuged (400 g for 10 minutes) to gain cell pellet and supernatant. The Mini-BAL supernatant was stored at -70&#x000b0;C in aliquots. The cell pellet was resuspended in Roswell Park Memorial Institute (RPMI) Medium. The cell count was carried out on a hemocytometer. Polymorphonuclear Neutrophil Granulocytes (PMN) were determined in a Wright-Giemsa stained cytocentrifuge smear, and a PMN vitality test was performed with Trypan Blue. The sample was then diluted to a concentration of 10<sup>6 </sup>cells/ml.</p></sec></sec><sec><title>ELISA for matrix metalloproteinases (MMP) and tissue inhibitor of MMP (TIMP)</title><p>MMP-8, MMP-9 and TIMP-1 concentrations in Mini-BAL supernatant were determined by specific ELISA (Biotrak ELISA, Amersham Biosciences, Germany) following the manufacturer's instructions. Each sample was assayed in duplicate and the values used for calculations were all within the linear proportion of the standard curve.</p></sec><sec><title>Gelatin zymography for matrix metalloproteinase activity</title><p>Sodiumdodecylsulfate gels containing 0.1% gelatine were used to identify gelatinolytic activity in Mini-BAL or plasma as described previously by Leber and Balkwill ([<xref ref-type="bibr" rid="B19">19</xref>], figure <xref ref-type="fig" rid="F1">1</xref>). MMP standard (MMP-2 and MMP-9) was loaded on each gel to identify the gelatinolytic enzymes. To quantify the gelatinolytic activity densitometrically, the bands were analyzed with E.A.S.Y.Win32 imaging software (Herolab, Germany). The bands were characterised in per-cent of the standard MMP-9 bands.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Gelatine zymography of mini-BAL from representative patients with hospital-acquired pneumonia (Lane 1&#x02013;7).</bold> MMP standard (lane 8). Gelatinolytic bands of pro-MMP-9 (92 kD), pro-MMP-9-lipocalin-complex (130 kD) and homodimeric MMP-9 (220 kD) are clearly visible.</p></caption><graphic xlink:href="1471-2466-8-12-1"/></fig></sec><sec><title>Statistical analyses</title><p>Statistical analyses were carried out with Statistica for Windows, Statistica<sup>&#x000ae; </sup>5.0 (Statsoft GmbH, Germany). Nonparametric tests such as Mann-Whitney U-test were used. Correlations were determined by the Spearman ranking test. Fisher's exact test (two tailed) was used for association of discontinuous variables. A p value of less than 0.05 was considered significant. The data are given as mean and standard error of the mean.</p></sec></sec><sec><title>Results</title><sec><title>Patients and controls</title><p>Demographic data of HAP patients are shown in table <xref ref-type="table" rid="T1">1</xref>. Reason for hospital admission was surgery in 73% and cardiovascular insufficiency in 26%. As comorbidity, 21%t of the patients had chronic lung disease, 21% chronic heart disease, 3% diabetes mellitus, 8% chronic gastrointestinal disease and 24% solid neoplasia. Twenty-three percent had no comorbidity.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic data (Mean &#x000b1; SEM) of 37 patients with HAP, including 17 patients with high-risk bacteria and 20 patients with low-risk bacteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>all HAP patients (n = 37)</bold></td><td align="left"><bold>high-risk bacteria (n = 17)</bold></td><td align="left"><bold>low-risk bacteria (n = 20)</bold></td><td align="left"><bold>*p-value</bold></td></tr></thead><tbody><tr><td align="left"><bold>number (n)</bold></td><td align="left">37</td><td align="left">17</td><td align="left">20</td><td></td></tr><tr><td align="left"><bold>age (years)</bold></td><td align="left">59.8 (&#x000b1; 2.6)</td><td align="left">59,3 (&#x000b1; 4,2)*</td><td align="left">60,3 (&#x000b1; 3,5)*</td><td align="left">*0.3</td></tr><tr><td align="left"><bold>male (%)</bold></td><td align="left">68</td><td align="left">70.6*</td><td align="left">40*</td><td align="left">*0.7</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>WBC (/nl)</bold></td><td align="left">12.3 (&#x000b1; 1.0)</td><td align="left">13,0 (&#x000b1; 1,5)*</td><td align="left">11,5 (&#x000b1; 1,5)*</td><td align="left">*0.20</td></tr><tr><td align="left"><bold>temperature (&#x000b0;C)</bold></td><td align="left">37.3 (&#x000b1; 0.18)</td><td align="left">37,5 (&#x000b1; 0,2)*</td><td align="left">37,0 (&#x000b1; 0,3)*</td><td align="left">*0.45</td></tr><tr><td align="left"><bold>CRP (ng/ml)</bold></td><td align="left">154.9 (&#x000b1; 29.5)</td><td align="left">152,6 (&#x000b1; 28,9)*</td><td align="left">157,9 (&#x000b1; 58,9)*</td><td align="left">*0.51</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>ventilated n (%)*</bold></td><td align="left">15 (41%)</td><td align="left">10 (59)*</td><td align="left">5 (25) *</td><td align="left">*0.05</td></tr><tr><td align="left"><bold>oxygenation ratio</bold></td><td align="left">266.8 (&#x000b1; 21.5)</td><td align="left">244,5 (&#x000b1; 33,9)*</td><td align="left">284,6 (&#x000b1; 27,9)*</td><td align="left">*0.4</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>CPIS</bold></td><td align="left">6 (&#x000b1; 0.35)</td><td align="left">6,2 (&#x000b1; 0,4)*</td><td align="left">5,0 (&#x000b1; 0,4)*</td><td align="left">*0.24</td></tr><tr><td align="left"><bold>PMN in BAL (%)</bold></td><td align="left">84,4 (&#x000b1; 3,2)</td><td align="left">83,6 (&#x000b1; 4,1)*</td><td align="left">87,3(&#x000b1; 1,6)*</td><td align="left">*0,71</td></tr><tr><td align="left"><bold>mortality (%)</bold></td><td align="left">8.1</td><td align="left">5.9*</td><td align="left">10*</td><td align="left">*1.0</td></tr></tbody></table><table-wrap-foot><p>*p- value between patients with high-risk and low-risk bacteria.</p></table-wrap-foot></table-wrap></sec><sec><title>Bacterial culture in mini-BAL</title><p>Bacterial culture data from Mini-Bal are shown in table <xref ref-type="table" rid="T2">2</xref>. From 37 patients with HAP, 17 patients had high-risk bacteria (<italic>S. aureus</italic>, <italic>P. aeruginosa or S. maltophilia) </italic>and 20 patients low-risk bacteria (Table <xref ref-type="table" rid="T2">2</xref>). Mini-BAL from the control patients remained sterile (control group).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Recovered bacteria in Mini-BAL from 37 HAP patients (&#x02265; 10<sup>3 </sup>CFU/ml).</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Bacteria in Mini-BAL</bold></td><td align="left"><bold>Number of patients</bold></td></tr></thead><tbody><tr><td align="left">High-risk bacteria</td><td></td></tr><tr><td align="left">&#x02003;&#x02022; <italic>S. aureus</italic></td><td align="left">9</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>P. aeruginosa</italic></td><td align="left">7</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>S. maltophilia</italic></td><td align="left">1</td></tr><tr><td align="left">Low-risk bacteria</td><td></td></tr><tr><td align="left">&#x02003;&#x02022; <italic>Klebsiella pneumoniae</italic></td><td align="left">4</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>E. coli</italic></td><td align="left">3</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>S. marcescens</italic></td><td align="left">2</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>S. pneumoniae</italic></td><td align="left">2</td></tr><tr><td align="left">&#x02003;&#x02022; &#x003b2;-hemolytic <italic>Streptococci</italic></td><td align="left">2</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>Citrobacter freundii</italic></td><td align="left">1</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>Enterobacter cloacae</italic></td><td align="left">1</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>Hafnia alvei</italic></td><td align="left">1</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>P. mirabilis</italic></td><td align="left">1</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>N. meningitidis</italic></td><td align="left">1</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>Branhamella catarrhalis</italic></td><td align="left">1</td></tr><tr><td align="left">&#x02003;&#x02022; <italic>Chlamydia pneumoniae*</italic></td><td align="left">1</td></tr></tbody></table><table-wrap-foot><p>* PCR</p></table-wrap-foot></table-wrap></sec><sec><title>MMP and TIMP in HAP versus control</title><p>When comparing HAP Patients with controls, MMP-8, MMP-9 concentrations were higher and TIMP-1 lower in Mini-BAL of HAP patients vs. controls without reaching significance (Table <xref ref-type="table" rid="T3">3</xref>). The molar MMP-9/TIMP-1 ratio and the gelatinolytic activity of MMP-9 was increased in HAP patients compared to controls (MMP-9/TIMP-1 ratio 0.43 (&#x000b1; 0.12) vs. 0.04 (&#x000b1; 0.02), p &#x0003c; 0.0001; MMP-9 activity 149 (&#x000b1; 41) vs. 34 (&#x000b1; 11), p = 0.0001). The activated form of MMP-9 (85 kDa) was seen in 68% versus 0% of controls (p &#x0003c; 0.0001).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>MMP, TIMP, MMP-9 activity and molar ratio in patients with HAP and control patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>Mean &#x000b1; SEM</bold></td><td align="center" colspan="2"><bold>p- value</bold></td></tr></thead><tbody><tr><td align="left"><bold>MMP-8 </bold>(ng/ml)</td><td></td><td></td><td></td></tr><tr><td align="left">Control group (n = 18)</td><td align="left">24 (&#x000b1; 7)</td><td align="left">HAP vs. control</td><td align="left">0.346</td></tr><tr><td align="left">All HAP patients (n = 37)</td><td align="left">435 (&#x000b1; 131)</td><td></td><td></td></tr><tr><td align="left">HAP subgroups</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02022; Bacteria</td><td></td><td align="left">high vs. low risk</td><td align="left">0.002</td></tr><tr><td align="left">&#x02003;&#x025cb; high-risk bacteria (n = 17)</td><td align="left">750 (&#x000b1; 245)</td><td align="left">high vs. control</td><td align="left">0.0007</td></tr><tr><td align="left">&#x02003;&#x025cb; low-risk bacteria (n = 20)</td><td align="left">167 (&#x000b1; 93)</td><td align="left">low vs. control</td><td align="left">0.198</td></tr><tr><td align="left">&#x02022; invasive ventilation</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x025cb; ventilated (n = 15)</td><td align="left">891 (&#x000b1; 266)</td><td align="left">vent. vs. not vent.</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; not ventilated (n = 22)</td><td align="left">124 (&#x000b1; 77)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>MMP-9 </bold>(ng/ml)</td><td></td><td></td><td></td></tr><tr><td align="left">Control group (n = 18)</td><td align="left">50 (&#x000b1; 17)*</td><td align="left">HAP vs. control</td><td align="left">0.059</td></tr><tr><td align="left">All HAP patients (n = 37)</td><td align="left">657 (&#x000b1; 157)*</td><td></td><td></td></tr><tr><td align="left">HAP subgroups</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02022; Bacteria</td><td></td><td align="left">high vs. low risk</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; high-risk bacteria (n = 17)</td><td align="left">1168 (&#x000b1; 266)**</td><td align="left">high vs. control</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; low-risk bacteria (n = 20)</td><td align="left">224 (&#x000b1; 119)**</td><td align="left">low vs. control</td><td align="left">0.497</td></tr><tr><td align="left">&#x02022; invasive ventilation</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x025cb; ventilated (n = 15)</td><td align="left">1309 (&#x000b1; 266)***</td><td align="left">vent. vs. not vent.</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; not ventilated (n = 22)</td><td align="left">213 (&#x000b1; 131)***</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>MMP-9 gelatinolytic activity </bold>(%)</td><td></td><td></td><td></td></tr><tr><td align="left">Control group (n = 18)</td><td align="left">34 (&#x000b1; 11)*</td><td align="left">HAP vs. control</td><td align="left">0.0001</td></tr><tr><td align="left">All HAP patients (n = 37)</td><td align="left">149 (&#x000b1; 41)*</td><td></td><td></td></tr><tr><td align="left">HAP subgroups</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02022; Bacteria</td><td></td><td align="left">high vs. low risk</td><td align="left">0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; high-risk bacteria (n = 17)</td><td align="left">325 (&#x000b1; 106)**</td><td align="left">high vs. control</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; low-risk bacteria (n = 20)</td><td align="left">67 (&#x000b1; 14)**</td><td align="left">low vs. control</td><td align="left">0.007</td></tr><tr><td align="left">&#x02022; invasive ventilation</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x025cb; ventilated (n = 15)</td><td align="left">197 (&#x000b1; 40)***</td><td align="left">vent. vs. not vent.</td><td align="left">0.0024</td></tr><tr><td align="left">&#x02003;&#x025cb; not ventilated (n = 22)</td><td align="left">118 (&#x000b1; 63)***</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>TIMP-1 </bold>(ng/ml)</td><td></td><td></td><td></td></tr><tr><td align="left">Control group (n = 18)</td><td align="left">410 (&#x000b1; 80)*</td><td align="left">HAP vs. control</td><td align="left">0.275</td></tr><tr><td align="left">All HAP patients (n = 37)</td><td align="left">648 (&#x000b1; 164)*</td><td></td><td></td></tr><tr><td align="left">HAP subgroups</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02022; Bacteria</td><td></td><td align="left">high vs. low risk</td><td align="left">0.0039</td></tr><tr><td align="left">&#x02003;&#x025cb; high-risk bacteria (n = 17)</td><td align="left">983 (&#x000b1; 285)**</td><td align="left">high vs. control</td><td align="left">0.290</td></tr><tr><td align="left">&#x02003;&#x025cb; low-risk bacteria (n = 20)</td><td align="left">364 (&#x000b1; 165)**</td><td align="left">low vs. control</td><td align="left">0.005</td></tr><tr><td align="left">&#x02022; invasive ventilation</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x025cb; ventilated (n = 15)</td><td align="left">1309 (&#x000b1; 261)***</td><td align="left">vent. vs. not vent.</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; not ventilated (n = 22)</td><td align="left">132 (&#x000b1; 40)***</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>MMP-9/TIMP-1 molar ratio</bold></td><td></td><td></td><td></td></tr><tr><td align="left">Control group (n = 18)</td><td align="left">0.04 (&#x000b1; 0.02)*</td><td align="left">HAP vs. control</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">All HAP patients (n = 37)</td><td align="left">0.43 (&#x000b1; 0.12)*</td><td></td><td></td></tr><tr><td align="left">HAP subgroups</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02022; Bacteria</td><td></td><td align="left">high vs. low risk</td><td align="left">0.0002</td></tr><tr><td align="left">&#x02003;&#x025cb; high-risk bacteria (n = 17)</td><td align="left">0.66 (&#x000b1; 0.17)**</td><td align="left">high vs. control</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;&#x025cb; low-risk bacteria (n = 20)</td><td align="left">0.24 (&#x000b1; 0.15)**</td><td align="left">low vs. control</td><td align="left">0.0028</td></tr><tr><td align="left">&#x02022; invasive ventilation</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x025cb; ventilated (n = 15)</td><td align="left">0.66 (&#x000b1; 0.23)***</td><td align="left">vent. vs. not vent.</td><td align="left">0.0046</td></tr><tr><td align="left">&#x02003;&#x025cb; not ventilated (n = 22)</td><td align="left">0.28 (&#x000b1; 0.12)***</td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>Subgroups according to high/low-risk bacteria and artificial ventilation.</p></table-wrap-foot></table-wrap><p>The results for MMP-9 in mini-BAL correlated significantly with the densitometric evaluation of MMP-9 in Zymography (r = 0.79; p &#x0003c; 0.001).</p></sec><sec><title>MMP and TIMP according to bacteria</title><p>In Patients with high-risk bacteria (<italic>S. aureus</italic>, <italic>P. aeruginosa or S. maltophilia </italic>infection), MMP-8-, MMP-9- and TIMP-1-concentrations, the MMP-9 gelatinolytic activity and the MMP-9/TIMP-1 molar ratio in mini-BAL were higher than in patients with low-risk bacteria (MMP-8 p = 0.002; MMP-9 p &#x0003c; 0.0001; TIMP-1 p = 0.0039; MMP-9 gelatinolytic activity p = 0.0002, molar ratio p = 0.0002) and control patients (Table <xref ref-type="table" rid="T3">3</xref>, figure <xref ref-type="fig" rid="F2">2</xref>). In addition, patients with high-risk bacteria had more often (16 out of 17) the activated form of MMP-9 (85 kDa) than patients with low-risk bacteria (9 out of 20, p &#x0003c; 0.005) and controls (0 out of 16, p &#x0003c; 0.0001)</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>MMP-8, MMP-9 and TIMP-1 concentration in mini-BAL from HAP patients and controls.</bold> Group 1 = HAP patients with high risk bacteria; group 2 = HAP patients with low-risk bacteria; group 3 = control patients (Mean and SEM).</p></caption><graphic xlink:href="1471-2466-8-12-2"/></fig><p>Interestingly, in patients with low-risk bacteria MMP-8, MMP-9 concentrations in mini-BAL were indifferent to controls (Table <xref ref-type="table" rid="T3">3</xref>), but TIMP-1 concentrations were lower (p = 0.005) associated with higher MMP-9 activity (p = 0.007) and MMP-9/TIMP-1 ratio (p = 0.003) than in controls (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>The quantitative pathogen count (CFU/ml) in Mini-BAL did not correlate with MMP- and TIMP-levels in Mini-BAL and blood (data not shown). Plasma levels did not differ significantly between patients with high-risk and low-risk bacteria (data not shown).</p></sec><sec><title>MMP and TIMP according to artificial ventilation</title><p>Ventilated patients (n = 15, all invasive ventilation with pressure controlled/BIPAP modus) had significantly higher MMP-8, MMP-9 and TIMP-1 concentrations, gelatinolytic MMP-9 activity and MMP-9/TIMP-1 molar ratio in mini-BAL than non-ventilated patients (n = 22) (MMP-8 p &#x0003c; 0.0001; MMP-9 p &#x0003c; 0.0001; TIMP-1 p &#x0003c; 0.0002; MMP-9 activity p &#x0003c; 0.005, molar ratio p &#x0003c; 0.006).</p><p>In zymography, the activated form of MMP-9 (85 kDa band) was seen in 93% of ventilated patients vs. 50% of non ventilated patients (p &#x0003c; 0.005).</p><p>Ventilation time (&#x02264; 7 days vs. &#x0003e;7 days) did not have an impact on MMP-levels in Mini-BAL (data not shown). Interestingly, invasive ventilation and high-risk bacteria seem to be additive for the increase of the MMP concentration in BAL (figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>MMP-8 (A), MMP-9 (B) and TIMP-1 (C) concentration in mini-BAL from patients with high-risk and low-risk bacteria in association with artificial ventilation.</bold> V = ventilated, NV = not ventilated.</p></caption><graphic xlink:href="1471-2466-8-12-3"/></fig><p>MMP plasma levels did not differ significantly between ventilated and non-ventilated patients (data not shown). TIMP-1 and the MMP-9/TIMP-1 molar ratio in plasma was higher in ventilated patients (TIMP-1 p = 0.014, molar ratio p = 0.046)</p></sec><sec><title>MMP and TIMP in correlation to clinical and laboratory parameters</title><sec><title>Pneumonia severity</title><p>In HAP patients no correlation was found between MMP-levels in Mini-BAL and the oxygenation index, the CPIS score or the PMN Mini-BAL percentage (data not shown).</p></sec><sec><title>Systemic inflammation (figure <xref ref-type="fig" rid="F3">3</xref>)</title><p>In HAP patients all Mini-BAL-concentrations correlated with serum-CRP (MMP-8: r = .78; p &#x0003c; .0001; MMP-9: r = .64; p &#x0003c; .0001; MMP-9 activity r = .69; p &#x0003c; 0.001; TIMP-1: r = .51; p = .002, MMP-9/TIMP-1 molar ratio r = .50; p = 0.002, figure <xref ref-type="fig" rid="F4">4</xref>), most Mini-BAL-concentrations correlated with body temperature (MMP-8: r = .52; p = .004; MMP-9: r = .35; p = 0.065, n.s.; MMP-9 activity r = .55; p = 0.014; TIMP-1: r = .48; p = .009; MMP-9/TIMP-1 molar ratio r = .08; p = 0.69, n.s.) and most Mini-BAL-concentrations correlated with serum leukocytes (MMP-8: r = .42; p = .008; MMP-9: r = .34; p = .034; MMP-9 activity r = .60; p = 0.0005; TIMP-1: r = .34; p = 0.04, MMP-9/TIMP-1 molar ratio r = .26; p = 0.11, n.s.).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>Correlation of MMP-8 (A), MMP-9 (B) and TIMP-1 (C) concentration in mini-BAL with serum CRP in patients with hospital-acquired pneumonia.</p></caption><graphic xlink:href="1471-2466-8-12-4"/></fig></sec></sec></sec><sec><title>Discussion</title><p>The main finding of our study is that nosocomial pulmonary infection with high-risk pathogens (<italic>S. aureus</italic>, <italic>P. aeruginosa or S. maltophilia) </italic>is associated with higher concentration and activation of metalloproteases locally in the lung, than nosocomial infection with other bacteria. In addition artificial ventilation was associated with additional increased MMP concentration and activation.</p><p>The role of the TIMP-MMP axis during inflammatory responses seems to be complex, data are limited.</p><p>Bacterial infection of the lower respiratory tract induces a proinflammatory milieu with the activation of MMP and inactivation of TIMP via several mechanisms. Attracted to the lung by IL-8 and leukrotrien B4 PMN secrete MMP-8 and MMP-9. MMP are activated by bacterial MMP [<xref ref-type="bibr" rid="B20">20</xref>], plasmin [<xref ref-type="bibr" rid="B21">21</xref>] or other neutrophil products such as myeloperoxidase and neutrophil elastase (NE). In addition NE inhibits TIMP-1 [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>In community-acquired pneumonia (CAP) Yang et al. found an excessive increase of MMP-9 activity and MMP-9 levels in plasma [<xref ref-type="bibr" rid="B9">9</xref>] but the local pulmonary TIMP-MMP balance was not investigated. Hartog et al. found increased activated pulmonary MMP in hospital-acquired pneumonia (HAP) with some evidence of increased MMP levels in patients with proven bacterial infection [<xref ref-type="bibr" rid="B8">8</xref>]. In line with these studies, we found in our study with HAP patients higher MMP-8 and MMP-9 BAL concentrations associated with significantly increased MMP-9 activity. A lot of data shows that, in chronic pulmonary diseases, an imbalance of proteases and inhibitors can induce consecutive degradation of the extracellular matrix of the lung [<xref ref-type="bibr" rid="B23">23</xref>]. Increased MMP secretion in association with cigarette smoke is discussed as a factor in COPD development and progression of COPD [<xref ref-type="bibr" rid="B24">24</xref>]. Segura-Valdez et al. have found increased levels of MMP-8 and MMP-9 in Mini-BAL and lung biopsies of COPD patients [<xref ref-type="bibr" rid="B25">25</xref>]. Zheng et al did show in bronchiectasis [<xref ref-type="bibr" rid="B26">26</xref>] neutrophil inflammation associated with MMP-8 and MMP-9 concentration. Sagel et al. have shown that cystic fibrosis (CF) patients show significantly elevated MMP levels with increased MMP-9/Timp-1 molar ratios [<xref ref-type="bibr" rid="B27">27</xref>]. Taghavi and coworkers have described increased MMP-9 and MMP-8 levels in bronchiolitis obliterans from lung transplant patients [<xref ref-type="bibr" rid="B28">28</xref>]. In addition, various lung injury models show that MMPs are strongly related to the pathogenesis of lung injury [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. The role of increased MMP-8 and MMP-9 concentrations and activity in bacterial infection of the lung is, in contrast to chronic disease, under debate. Besides tissue destructive effects, increased MMP activation might be involved in host defence mechanism inducing bacterial eradication [<xref ref-type="bibr" rid="B32">32</xref>] and might have a protective effect against pulmonary fibrosis following inflammation [<xref ref-type="bibr" rid="B33">33</xref>]. In animal models MMP-9 deficiency is associated with impaired host defence against abdominal sepsis, with reduced bacterial clearance [<xref ref-type="bibr" rid="B10">10</xref>]. MMP-9 is known to be a major factor in neutrophil migration across basement membranes [<xref ref-type="bibr" rid="B34">34</xref>]. MMP-9 -/- mice displayed diminished recruitment of leucocytes to the site of infection [<xref ref-type="bibr" rid="B10">10</xref>]. On the other hand experimental pulmonary infections with <italic>Francisella tularensis </italic>in MMP-9 wildtype mice did show an increased neutrophil inflammation of the lung accompanied by increased bacterial burden and mortality compared to MMP-9 -/- animals [<xref ref-type="bibr" rid="B35">35</xref>].</p><p>Since pathogens interact with the TIMP-MMP axis, induction of the MMP concentration and activity might be related to different species. Oggioni et al. have found a pneumococcal zinc metalloproteinase to cleave and thus to activate MMP-9 in a murine model of pneumonia and meningitis. In certain mutants this leads to a more severe course of disease than in other isolates of pneumococci [<xref ref-type="bibr" rid="B20">20</xref>]. This indicates that different bacterial strains and species have a different impact on MMP secretion and activation. Indeed, in the present study, in patients with high-risk pathogens (<italic>S. aureus</italic>, <italic>P. aeruginosa or S. maltophilia) </italic>we found significantly higher MMP-8 and MMP-9 BAL concentration locally in the lung associated with increased MMP-9/Timp-1 molar ratio and MMP-9-activity compared to patients with low-risk bacteria and to controls (Table <xref ref-type="table" rid="T3">3</xref>). High-risk pathogens seem to induce a strong neutrophil MMP release. In contrast, patients with low-risk bacteria have, compared to controls, only an insignificant increase of MMP. Due to low inhibitor concentrations, these patients still have active MMP-9 (Table <xref ref-type="table" rid="T3">3</xref>). Low MMP increment and activation in HAP-patients with low-risk bacteria might be explained by less virulence of these bacteria. In addition, a positive bacterial culture in patients with a clinical diagnose of HAP according to the ATS criteria [<xref ref-type="bibr" rid="B4">4</xref>] is not 100% specific to detect HAP. Compared to post-mortal histopathology, the specificity of the ATS criteria to define HAP is only 70 to 80% [<xref ref-type="bibr" rid="B36">36</xref>]. Some of the HAP patients with low-risk bacteria (diagnosed by ATS criteria) and low MMP activation might not have significant pneumonia when histopathologic examination is performed. Clinicians should be aware that detecting bacteria does not always distinguish between airway colonization and invasive infection.</p><p>Interestingly we found in HAP patients a close correlation between pulmonary MMP levels and laboratory parameters of systemic inflammation. Increased pulmonary MMP was associated with higher serum-CRP, higher white blood count and higher body temperature (Figure <xref ref-type="fig" rid="F2">2</xref>). MMP activation in HAP might be necessary for bacterial clearance, but unresolved infection might trigger ongoing MMP activation and tissue destruction[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. MMP concentration and activation seems to be a marker for the severity of inflammation and might be, in case of very low concentration, a diagnostic tool.</p><p>In addition to bacterial infection, ventilation associated lung trauma and inflammation is of great interest. Foda et al. discussed the role of MMP in ventilator-induced lung injury [<xref ref-type="bibr" rid="B14">14</xref>]. They suggested high-volume ventilation as a leading cause of lung injury. This is due to release of TNF-alpha and interleukines and thus upregulation of MMP. Halbertsma states that the biotrauma associated with mechanical ventilation causes cytokine release (IL-6, IL-8, TNF-alpha) with consecutive PMN recruitment to the lung [<xref ref-type="bibr" rid="B13">13</xref>]. In spite of the fact that all ventilated patients have been ventilated with modern pressure control ventilation, we found significantly higher MMP and Timp-1 levels in BAL from ventilated patients compared to non-ventilated patients. Since 2/3 of the ventilated patients were infected with high-risk bacteria, these data are difficult to evaluate. When looking at subgroups, both factors, ventilation and high-risk bacteria, seem to have an additive effect on MMP release and activation (figure <xref ref-type="fig" rid="F2">2</xref>). HAP-Patients with high-risk bacteria and ventilation have the highest values. In line with this, it has been shown in animal models that both stretch during ventilation and stimulation with bacterial antigen, activate nuclear factor B, followed by cytokine release [<xref ref-type="bibr" rid="B37">37</xref>]. Mechanical stretch of human lung endothelium is associated with MMP release [<xref ref-type="bibr" rid="B38">38</xref>]. Other authors have shown an upregulation of MMP during ventilator associated lung injury in a rat model. In this setting, inhibition of MMP activity reduced lung injury [<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec><title>Conclusion</title><p>In conclusion high amounts of active MMP are found in BAL from patients with HAP, which is most prominent in patients with high-risk bacteria and patients with artificial ventilation. Bacteria and ventilation trauma seems to induce neutrophil inflammation and metalloprotease activation. The pulmonary MMP concentration is closely correlated to systemic signs of inflammation. The pathophysiologic role of this local MMP-inflammation is under debate.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CL carried out the ELISA and zymography and was involved in the design of the study and drafting the manuscript. BS, KD, VK and DD conducted the clinical part of the study, were involved in the design and coordination of the study and drafting the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2466/8/12/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank H. Richartz and U. Wegener for excellent technical assistance.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>JP</given-names><suffix>III</suffix></name></person-group><article-title>Hospital-acquired pneumonia: risk factors, microbiology, and treatment</article-title><source>Chest</source><year>2001</year><volume>119</volume><fpage>373S</fpage><lpage>384S</lpage><pub-id pub-id-type="pmid">11171773</pub-id><pub-id pub-id-type="doi">10.1378/chest.119.2_suppl.373S</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowton</surname><given-names>DL</given-names></name></person-group><article-title>Nosocomial pneumonia in the ICU--year 2000 and beyond</article-title><source>Chest</source><year>1999</year><volume>115</volume><fpage>28S</fpage><lpage>33S</lpage><pub-id pub-id-type="pmid">10084457</pub-id><pub-id pub-id-type="doi">10.1378/chest.115.suppl_1.28S</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Babcock</surname><given-names>HM</given-names></name><name><surname>Zack</surname><given-names>JE</given-names></name><name><surname>Garrison</surname><given-names>T</given-names></name><name><surname>Trovillion</surname><given-names>E</given-names></name><name><surname>Kollef</surname><given-names>MH</given-names></name><name><surname>Fraser</surname><given-names>VJ</given-names></name></person-group><article-title>Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location</article-title><source>Infect Control Hosp Epidemiol</source><year>2003</year><volume>24</volume><fpage>853</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">14649775</pub-id><pub-id pub-id-type="doi">10.1086/502149</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kollef</surname><given-names>MH</given-names></name></person-group><article-title>What is ventilator-associated pneumonia and why is it important?</article-title><source>Respir Care</source><year>2005</year><volume>50</volume><fpage>714</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">15913464</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borregaard</surname><given-names>N</given-names></name><name><surname>Theilgaard-Monch</surname><given-names>K</given-names></name><name><surname>Sorensen</surname><given-names>OE</given-names></name><name><surname>Cowland</surname><given-names>JB</given-names></name></person-group><article-title>Regulation of human neutrophil granule protein expression</article-title><source>Curr Opin Hematol</source><year>2001</year><volume>8</volume><fpage>23</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">11138622</pub-id><pub-id pub-id-type="doi">10.1097/00062752-200101000-00005</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohbayashi</surname><given-names>H</given-names></name></person-group><article-title>Matrix metalloproteinases in lung diseases</article-title><source>Curr Protein Pept Sci</source><year>2002</year><volume>3</volume><fpage>409</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">12370004</pub-id><pub-id pub-id-type="doi">10.2174/1389203023380549</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>Neutrophils and protease/antiprotease imbalance</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><fpage>S49</fpage><lpage>S52</lpage><pub-id pub-id-type="pmid">10556170</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hartog</surname><given-names>CM</given-names></name><name><surname>Wermelt</surname><given-names>JA</given-names></name><name><surname>Sommerfeld</surname><given-names>CO</given-names></name><name><surname>Eichler</surname><given-names>W</given-names></name><name><surname>Dalhoff</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name></person-group><article-title>Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">12588713</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200203-258OC</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SF</given-names></name><name><surname>Chu</surname><given-names>SC</given-names></name><name><surname>Chiang</surname><given-names>IC</given-names></name><name><surname>Kuo</surname><given-names>WF</given-names></name><name><surname>Chiou</surname><given-names>HL</given-names></name><name><surname>Chou</surname><given-names>FP</given-names></name><name><surname>Kuo</surname><given-names>WH</given-names></name><name><surname>Hsieh</surname><given-names>YS</given-names></name></person-group><article-title>Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia</article-title><source>Clin Chim Acta</source><year>2005</year><volume>352</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">15653116</pub-id><pub-id pub-id-type="doi">10.1016/j.cccn.2004.09.025</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Renckens</surname><given-names>R</given-names></name><name><surname>Roelofs</surname><given-names>JJ</given-names></name><name><surname>Florquin</surname><given-names>S</given-names></name><name><surname>de Vos</surname><given-names>AF</given-names></name><name><surname>Lijnen</surname><given-names>HR</given-names></name><name><surname>van't Veer</surname><given-names>C</given-names></name><name><surname>van der</surname><given-names>PT</given-names></name></person-group><article-title>Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><fpage>3735</fpage><lpage>3741</lpage><pub-id pub-id-type="pmid">16517742</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerrigan</surname><given-names>JJ</given-names></name><name><surname>Mansell</surname><given-names>JP</given-names></name><name><surname>Sandy</surname><given-names>JR</given-names></name></person-group><article-title>Matrix turnover</article-title><source>J Orthod</source><year>2000</year><volume>27</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">11099555</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadoglou</surname><given-names>NP</given-names></name><name><surname>Liapis</surname><given-names>CD</given-names></name></person-group><article-title>Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms</article-title><source>Curr Med Res Opin</source><year>2004</year><volume>20</volume><fpage>419</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">15119978</pub-id><pub-id pub-id-type="doi">10.1185/030079904125003143</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halbertsma</surname><given-names>FJ</given-names></name><name><surname>Vaneker</surname><given-names>M</given-names></name><name><surname>Scheffer</surname><given-names>GJ</given-names></name><name><surname>van der Hoeven</surname><given-names>JG</given-names></name></person-group><article-title>Cytokines and biotrauma in ventilator-induced lung injury: a critical review of the literature</article-title><source>Neth J Med</source><year>2005</year><volume>63</volume><fpage>382</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">16301759</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foda</surname><given-names>HD</given-names></name><name><surname>Rollo</surname><given-names>EE</given-names></name><name><surname>Drews</surname><given-names>M</given-names></name><name><surname>Conner</surname><given-names>C</given-names></name><name><surname>Appelt</surname><given-names>K</given-names></name><name><surname>Shalinsky</surname><given-names>DR</given-names></name><name><surname>Zucker</surname><given-names>S</given-names></name></person-group><article-title>Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340)</article-title><source>Am J Respir Cell Mol Biol</source><year>2001</year><volume>25</volume><fpage>717</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">11726397</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>B</given-names></name><name><surname>Dalhoff</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name></person-group><article-title>Impaired neutrophil exocytosis in patients with severe pneumonia</article-title><source>Intensive Care Med</source><year>1999</year><volume>25</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">10051077</pub-id><pub-id pub-id-type="doi">10.1007/s001340050785</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pugin</surname><given-names>J</given-names></name><name><surname>Auckenthaler</surname><given-names>R</given-names></name><name><surname>Mili</surname><given-names>N</given-names></name><name><surname>Janssens</surname><given-names>JP</given-names></name><name><surname>Lew</surname><given-names>PD</given-names></name><name><surname>Suter</surname><given-names>PM</given-names></name></person-group><article-title>Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid</article-title><source>Am Rev Respir Dis</source><year>1991</year><volume>143</volume><fpage>1121</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">2024824</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papazian</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Garbe</surname><given-names>L</given-names></name><name><surname>Guignon</surname><given-names>I</given-names></name><name><surname>Thirion</surname><given-names>X</given-names></name><name><surname>Charrel</surname><given-names>J</given-names></name><name><surname>Bollet</surname><given-names>C</given-names></name><name><surname>Fuentes</surname><given-names>P</given-names></name><name><surname>Gouin</surname><given-names>F</given-names></name></person-group><article-title>Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>152</volume><fpage>1982</fpage><lpage>1991</lpage><pub-id pub-id-type="pmid">8520766</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalhoff</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Kothe</surname><given-names>H</given-names></name><name><surname>Korber</surname><given-names>M</given-names></name><name><surname>Pein</surname><given-names>M</given-names></name><name><surname>Wiessmann</surname><given-names>KJ</given-names></name></person-group><article-title>Oxidative metabolism of pulmonary phagocytes in acute pneumonia</article-title><source>Respiration</source><year>1994</year><volume>61</volume><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">8047717</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leber</surname><given-names>TM</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name></person-group><article-title>Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels</article-title><source>Anal Biochem</source><year>1997</year><volume>249</volume><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">9193704</pub-id><pub-id pub-id-type="doi">10.1006/abio.1997.2170</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oggioni</surname><given-names>MR</given-names></name><name><surname>Memmi</surname><given-names>G</given-names></name><name><surname>Maggi</surname><given-names>T</given-names></name><name><surname>Chiavolini</surname><given-names>D</given-names></name><name><surname>Iannelli</surname><given-names>F</given-names></name><name><surname>Pozzi</surname><given-names>G</given-names></name></person-group><article-title>Pneumococcal zinc metalloproteinase ZmpC cleaves human matrix metalloproteinase 9 and is a virulence factor in experimental pneumonia</article-title><source>Mol Microbiol</source><year>2003</year><volume>49</volume><fpage>795</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">12864860</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03596.x</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashiro</surname><given-names>S</given-names></name><name><surname>Kamohara</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Gong</surname><given-names>WH</given-names></name><name><surname>Yoshimura</surname><given-names>T</given-names></name></person-group><article-title>Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses</article-title><source>J Leukoc Biol</source><year>2001</year><volume>69</volume><fpage>698</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">11358976</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taggart</surname><given-names>CC</given-names></name><name><surname>Greene</surname><given-names>CM</given-names></name><name><surname>Carroll</surname><given-names>TP</given-names></name><name><surname>O'Neill</surname><given-names>SJ</given-names></name><name><surname>McElvaney</surname><given-names>NG</given-names></name></person-group><article-title>Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>171</volume><fpage>1070</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">15695494</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200407-881PP</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>DR</given-names></name><name><surname>Beaudry</surname><given-names>PP</given-names></name><name><surname>Laing</surname><given-names>TD</given-names></name><name><surname>Kowal</surname><given-names>V</given-names></name><name><surname>Leco</surname><given-names>KJ</given-names></name><name><surname>Leco</surname><given-names>PA</given-names></name><name><surname>Lim</surname><given-names>MS</given-names></name></person-group><article-title>The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth</article-title><source>Int J Obes Relat Metab Disord</source><year>1996</year><volume>20 Suppl 3</volume><fpage>S9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">8680484</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vernooy</surname><given-names>JH</given-names></name><name><surname>Lindeman</surname><given-names>JH</given-names></name><name><surname>Jacobs</surname><given-names>JA</given-names></name><name><surname>Hanemaaijer</surname><given-names>R</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name></person-group><article-title>Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD</article-title><source>Chest</source><year>2004</year><volume>126</volume><fpage>1802</fpage><lpage>1810</lpage><pub-id pub-id-type="pmid">15596677</pub-id><pub-id pub-id-type="doi">10.1378/chest.126.6.1802</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segura-Valdez</surname><given-names>L</given-names></name><name><surname>Pardo</surname><given-names>A</given-names></name><name><surname>Gaxiola</surname><given-names>M</given-names></name><name><surname>Uhal</surname><given-names>BD</given-names></name><name><surname>Becerril</surname><given-names>C</given-names></name><name><surname>Selman</surname><given-names>M</given-names></name></person-group><article-title>Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD</article-title><source>Chest</source><year>2000</year><volume>117</volume><fpage>684</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">10712992</pub-id><pub-id pub-id-type="doi">10.1378/chest.117.3.684</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Lam</surname><given-names>WK</given-names></name><name><surname>Tipoe</surname><given-names>GL</given-names></name><name><surname>Shum</surname><given-names>IH</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Leung</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ooi</surname><given-names>GC</given-names></name><name><surname>Tsang</surname><given-names>KW</given-names></name></person-group><article-title>Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways <italic>in vivo</italic></article-title><source>Eur Respir J</source><year>2002</year><volume>20</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">12166566</pub-id><pub-id pub-id-type="doi">10.1183/09031936.02.00282402</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sagel</surname><given-names>SD</given-names></name><name><surname>Kapsner</surname><given-names>RK</given-names></name><name><surname>Osberg</surname><given-names>I</given-names></name></person-group><article-title>Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis</article-title><source>Pediatr Pulmonol</source><year>2005</year><volume>39</volume><fpage>224</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">15635615</pub-id><pub-id pub-id-type="doi">10.1002/ppul.20165</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taghavi</surname><given-names>S</given-names></name><name><surname>Krenn</surname><given-names>K</given-names></name><name><surname>Jaksch</surname><given-names>P</given-names></name><name><surname>Klepetko</surname><given-names>W</given-names></name><name><surname>Aharinejad</surname><given-names>S</given-names></name></person-group><article-title>Broncho-alveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans</article-title><source>Am J Transplant</source><year>2005</year><volume>5</volume><fpage>1548</fpage><lpage>1552</lpage><pub-id pub-id-type="pmid">15888067</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-6143.2005.00865.x</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>DF</given-names></name><name><surname>Shanley</surname><given-names>TP</given-names></name><name><surname>Warner</surname><given-names>RL</given-names></name><name><surname>Murphy</surname><given-names>HS</given-names></name><name><surname>Varani</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>KJ</given-names></name></person-group><article-title>Role of matrix metalloproteinases in models of macrophage-dependent acute lung injury. Evidence for alveolar macrophage as source of proteinases</article-title><source>Am J Respir Cell Mol Biol</source><year>1999</year><volume>20</volume><fpage>1145</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">10340933</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Suk</surname><given-names>MH</given-names></name><name><surname>Yoon</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Hur</surname><given-names>GY</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Jeong</surname><given-names>HC</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Suh</surname><given-names>IB</given-names></name><name><surname>Shin</surname><given-names>C</given-names></name><name><surname>Shim</surname><given-names>JJ</given-names></name><name><surname>In</surname><given-names>KH</given-names></name><name><surname>Yoo</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>KH</given-names></name></person-group><article-title>Inhibition of matrix metalloproteinase-9 prevents neutrophilic inflammation in ventilator-induced lung injury</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2006</year><volume>291</volume><fpage>L580</fpage><lpage>L587</lpage><pub-id pub-id-type="pmid">16698855</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00270.2005</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Omoto</surname><given-names>Y</given-names></name><name><surname>Yamakawa</surname><given-names>Y</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Kiriyama</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name></person-group><article-title>Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury</article-title><source>J Heart Lung Transplant</source><year>2001</year><volume>20</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">11404174</pub-id><pub-id pub-id-type="doi">10.1016/S1053-2498(01)00250-9</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bottcher</surname><given-names>T</given-names></name><name><surname>Spreer</surname><given-names>A</given-names></name><name><surname>Azeh</surname><given-names>I</given-names></name><name><surname>Nau</surname><given-names>R</given-names></name><name><surname>Gerber</surname><given-names>J</given-names></name></person-group><article-title>Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis</article-title><source>Neurosci Lett</source><year>2003</year><volume>338</volume><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">12581831</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3940(02)01406-4</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanchou</surname><given-names>J</given-names></name><name><surname>Corbel</surname><given-names>M</given-names></name><name><surname>Tanguy</surname><given-names>M</given-names></name><name><surname>Germain</surname><given-names>N</given-names></name><name><surname>Boichot</surname><given-names>E</given-names></name><name><surname>Theret</surname><given-names>N</given-names></name><name><surname>Clement</surname><given-names>B</given-names></name><name><surname>Lagente</surname><given-names>V</given-names></name><name><surname>Malledant</surname><given-names>Y</given-names></name></person-group><article-title>Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">12576963</pub-id><pub-id pub-id-type="doi">10.1097/01.CCM.0000048626.02184.F8</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delclaux</surname><given-names>C</given-names></name><name><surname>Delacourt</surname><given-names>C</given-names></name><name><surname>d'Ortho</surname><given-names>MP</given-names></name><name><surname>Boyer</surname><given-names>V</given-names></name><name><surname>Lafuma</surname><given-names>C</given-names></name><name><surname>Harf</surname><given-names>A</given-names></name></person-group><article-title>Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane</article-title><source>Am J Respir Cell Mol Biol</source><year>1996</year><volume>14</volume><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">8845180</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Bakshi</surname><given-names>CS</given-names></name><name><surname>McCabe</surname><given-names>K</given-names></name><name><surname>Catlett</surname><given-names>SV</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Jackson</surname><given-names>PL</given-names></name><name><surname>Gaggar</surname><given-names>A</given-names></name><name><surname>Metzger</surname><given-names>DW</given-names></name><name><surname>Melendez</surname><given-names>JA</given-names></name><name><surname>Blalock</surname><given-names>JE</given-names></name><name><surname>Sellati</surname><given-names>TJ</given-names></name></person-group><article-title>Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of <italic>Francisella tularensis</italic></article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>1013</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">17202364</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabregas</surname><given-names>N</given-names></name><name><surname>Ewig</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>El Ebiary</surname><given-names>M</given-names></name><name><surname>Ramirez</surname><given-names>J</given-names></name><name><surname>de la Bellacasa</surname><given-names>JP</given-names></name><name><surname>Bauer</surname><given-names>T</given-names></name><name><surname>Cabello</surname><given-names>H</given-names></name></person-group><article-title>Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies</article-title><source>Thorax</source><year>1999</year><volume>54</volume><fpage>867</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">10491448</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uhlig</surname><given-names>U</given-names></name><name><surname>Fehrenbach</surname><given-names>H</given-names></name><name><surname>Lachmann</surname><given-names>RA</given-names></name><name><surname>Goldmann</surname><given-names>T</given-names></name><name><surname>Lachmann</surname><given-names>B</given-names></name><name><surname>Vollmer</surname><given-names>E</given-names></name><name><surname>Uhlig</surname><given-names>S</given-names></name></person-group><article-title>Phosphoinositide 3-OH kinase inhibition prevents ventilation-induced lung cell activation</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>169</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">14578214</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200303-343OC</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haseneen</surname><given-names>NA</given-names></name><name><surname>Vaday</surname><given-names>GG</given-names></name><name><surname>Zucker</surname><given-names>S</given-names></name><name><surname>Foda</surname><given-names>HD</given-names></name></person-group><article-title>Mechanical stretch induces MMP-2 release and activation in lung endothelium: role of EMMPRIN</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2003</year><volume>284</volume><fpage>L541</fpage><lpage>L547</lpage><pub-id pub-id-type="pmid">12456388</pub-id></citation></ref></ref-list></back></article> 